Sangui Biotech International, Inc.

Equities

SBH

US80105B1017

Biotechnology & Medical Research

End-of-day quote Hanseatische Wertpapierboerse Hamburg Other stock markets 23:00:00 19/03/2024 GMT			5-day change	1st Jan Change
0.002 ^EUR	-20.00%		-.--%	-33.33%

02-15	Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021

September 28, 2021 at 07:37 pm

Sangui Biotech International, Inc. announced earnings results for the full year ended June 30, 2021. For the full year, the company announced operating loss was USD 151,138 compared to USD 181,394 a year ago. Net loss was USD 198,890 compared to USD 192,741 a year ago.

Latest news about Sangui Biotech International, Inc.

Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-14	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	12/05/23	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	07/02/23	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	10/11/22	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	28/09/22	CI
Sangui Biotech International, Inc. Auditor Raises 'Going Concern' Doubt	27/09/22	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	16/05/22	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	11/02/22	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	12/11/21	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	28/09/21	CI
Sangui Biotech International, Inc. Auditor Raises 'Going Concern' Doubt	27/09/21	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	07/05/21	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020	09/02/21	CI
Sangui Biotech International, Inc. Announces Earnings Results for the First Quarter Ended September 30, 2020	13/11/20	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020	30/09/20	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020	14/05/20	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019	13/02/20	CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	13/11/19	CI
Sangui Biotech International, Inc. Reports Sales Results for the Fiscal Year of 2019	09/10/19	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	08/10/19	CI
Sangui Biotech International Inc. Announces Earnings Results for the Third Quarter and Nine Months Fiscal Year 2019	14/05/19	CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2019	13/05/19	CI
Sangui Biotech International, Inc. Announces Earnings Results for the Second Quarter and First Half of 2019	14/02/19	CI
Sangui Biotech International, Inc. Announces Earnings Results for the First Quarter Ended September 30, 2018	15/11/18	CI

Chart Sangui Biotech International, Inc.

Duration

Period

Chart Sangui Biotech International, Inc.

More charts

Company Profile

Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SANGUI BIOTECH INTERNATIONAL, INC.	-33.33%	450K
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+45.72%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research